

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

14 December 2022

FIRST PATIENTS SELECTED AND ENROLLED INTO RESPIRI's wheezo® MINNESOTA LUNG CENTER (MLC) REMOTE PATIENT MONITORING (RPM) PILOT PROGRAM.

Highlights:

- Respi and Access Telehealth RPM solutions under the supervision MLC have commenced onboarding patients in the short pilot wheezo® RPM program.
- RPM Current Procedural Terminology (CPT) reimbursement claims and first revenues to Respi to be processed within the next 2 months.
- Respi will receive recurring RPM revenues per patient per month in addition to wheezo® device sales.

Respi Limited (ASX:RSH) ("Respi" or the "Company"), an eHealth SaaS Company supporting respiratory health management is pleased to announce that the recently announced Minnesota Lung Center wheezo® RPM pilot program patient selection (refer announcement 18 November 2022) has been finalised and patient onboarding has successfully commenced. RPM partner Access Telehealth will provide a full RPM solution that includes the Remotli platform, patient engagement and remote monitoring to these patients, under the supervision of MLC. The pilot program has been reduced from 3-months to 2-months after which the wheezo® RPM program will be integrated into MLC systems and workflow and rolled-out as part of standard of care to respiratory patients with both asthma and/or COPD (Chronic Obstructive Pulmonary Disease).

RPM (CPT) reimbursement codes from this program will be processed through Centers for Medicare and Medicaid Services (CMS) and private insurers to ensure MLC is remunerated for providing this important and cost-effective patient service. In addition to the device sale, Respi will receive recurring RPM revenues per patient, per month for reimbursed services claimed by MLC which will include relevant RPM and possible Chronic Care Management (CCM) CPT codes. MLC provides ongoing care to thousands of existing respiratory patients and to new patient referrals from other physicians, all of which are potential candidates for the wheezo® RPM program.

Marjan Mikel, CEO of Respi said, "The wheezo® RPM program has the potential to make material differences to the lives of many respiratory patients. The relationship we have developed with Minnesota Lung Centre and Access Telehealth allows Respi to deliver a unique world class solution and future commercial rewards."

Respi together with RPM partners are in advanced discussions with a number of other potential wheezo® RPM customers who have recognized the benefits of introducing RPM services as part of their patient standard of care.

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respi Limited

Mr Nicholas Smedley
Executive Chairman
Respi Limited

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

P: +61 408 462 873

E: marjan@respiri.co

P: +61 447 074 160

E: nicholas@respiri.co

wheezeo® is a registered trademark of Respiri Limited.

About Respiri Limited

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an international e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US remote patient monitoring market. Its world-first technology detects wheeze, a typical symptom of Asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri created technology optimises how patients in partnership with their physicians manage chronic respiratory conditions. These solutions can help transform the way physicians interact with respiratory patients while they are away from the clinic. wheezeo®, is an FDA cleared Class II Medical Device, the respiri™ app (patient-user-interface) and the secure health portal can help different health organisations and providers connect with patients to improve collaboration and help improve respiratory condition management. In the USA, wheezeo® can be integrated into Remote Patient Monitoring (RPM) programs and qualifies for RPM Current Procedural Terminology (CPT) reimbursement.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world with respiratory disorders and dramatically reduce hospital admissions and the economic burden of Asthma and COPD. Respiri Limited's operations are based in Melbourne, Australia with offices in New York City, USA.

For additional information about Respiri Limited please visit our corporate website www.respiri.co/au

About wheezeo®

Developed in Australia, with the support of an international panel leading respiratory specialists and other healthcare professionals, the innovative wheezeo® device analyses breath sounds for wheeze, and the intuitive mobile application engages patients to log symptoms and triggers to build a personal profile to share data with healthcare providers so patients and physicians can have more informed discussions in relation to symptoms. The platform has been designed to extend care beyond the clinic which may lead to better health outcomes and improved quality of life for patients.

For information about our product offering in the US including wheezeo® please visit www.respiri.co/us

wheezeo® is a registered trademark of Respiri Limited.

About Access Telehealth

Access Telehealth is a digital health company dedicated to delivering innovative connected care solutions for management of people living with chronic disease. The Remotli platform uniquely simplifies remote care delivery with patient engagement and productivity driven dashboard tools to support effective patient care and compliance. Automated care-time tracking, and reimbursement reports makes it easy to boost revenue to support vital chronic disease management programs including Remote Physiologic Monitoring, Remote Therapeutic Monitoring, Transitional Care, Chronic Care Management, Telemedicine and more. Focusing on Remote Physiologic Monitoring and virtual care initiatives, the Access Telehealth clinical team delivers patient-centric remote monitoring services to support disease specific chronic care programs for health systems, payors, and providers, to enhance care delivery. www.accessrpm.com/

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

